ATE252912T1 - Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung - Google Patents

Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung

Info

Publication number
ATE252912T1
ATE252912T1 AT99930089T AT99930089T ATE252912T1 AT E252912 T1 ATE252912 T1 AT E252912T1 AT 99930089 T AT99930089 T AT 99930089T AT 99930089 T AT99930089 T AT 99930089T AT E252912 T1 ATE252912 T1 AT E252912T1
Authority
AT
Austria
Prior art keywords
treatment
bowel syndrome
composition
functional dyspepsia
pharmaceutical composition
Prior art date
Application number
AT99930089T
Other languages
English (en)
Inventor
Per Hellstroem
Suad Efendic
Original Assignee
Melacure Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melacure Therapeutics Ab filed Critical Melacure Therapeutics Ab
Application granted granted Critical
Publication of ATE252912T1 publication Critical patent/ATE252912T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT99930089T 1998-06-11 1999-06-08 Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung ATE252912T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802080A SE9802080D0 (sv) 1998-06-11 1998-06-11 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
PCT/SE1999/000997 WO1999064060A1 (en) 1998-06-11 1999-06-08 Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein

Publications (1)

Publication Number Publication Date
ATE252912T1 true ATE252912T1 (de) 2003-11-15

Family

ID=20411665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99930089T ATE252912T1 (de) 1998-06-11 1999-06-08 Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung

Country Status (19)

Country Link
US (1) US6348447B1 (de)
EP (2) EP1405642A1 (de)
JP (2) JP2002517468A (de)
AT (1) ATE252912T1 (de)
AU (1) AU738994B2 (de)
CA (1) CA2321700C (de)
CZ (1) CZ300873B6 (de)
DE (1) DE69912434T2 (de)
DK (1) DK1094834T3 (de)
ES (1) ES2205845T3 (de)
HU (1) HUP0103147A3 (de)
NO (1) NO327738B1 (de)
NZ (1) NZ506163A (de)
PL (1) PL198802B1 (de)
PT (1) PT1094834E (de)
RU (1) RU2226402C2 (de)
SE (1) SE9802080D0 (de)
WO (1) WO1999064060A1 (de)
ZA (1) ZA200004080B (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
CN1487836A (zh) 2000-03-14 2004-04-07 埃米林药品公司 胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001263230B2 (en) * 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003208945B2 (en) 2002-02-20 2008-05-01 Emisphere Technologies, Inc Method for administering GLP-1 molecules
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
DE602004025569D1 (de) 2003-06-18 2010-04-01 Tranzyme Pharma Inc Makrozyklische motilin rezeptorantagonisten
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
JP2008536881A (ja) * 2005-04-21 2008-09-11 ガストロテック・ファルマ・アクティーゼルスカブ Glp−1分子と制吐剤との医薬製剤
SI1881850T1 (sl) 2005-05-13 2011-01-31 Lilly Co Eli Glp-1 pegilirane spojine
MX2008001468A (es) 2005-06-30 2008-04-07 Sod Conseils Rech Applic Composiciones farmaceuticas del peptido similar al glucagon-1.
ES2532666T3 (es) * 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
RU2445972C2 (ru) * 2006-12-29 2012-03-27 Ипсен Фарма С.А.С. Фармацевтические композиции glp-1
US8236760B2 (en) * 2007-04-27 2012-08-07 Cedars-Sinsai Medical Center Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
KR20100090692A (ko) * 2007-10-24 2010-08-16 맨카인드 코포레이션 활성제의 전달
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Glp-1에 의한 유해 효과의 예방 방법
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BRPI0914889A2 (pt) 2008-06-17 2015-11-24 Otsuka Chemical Co Ltd peptídeo glp-1 adicionado de cadeia oligossacarídica
EP2609954B1 (de) 2008-06-20 2021-12-29 MannKind Corporation Interaktives Gerät für die Echtzeit-Profilierung von Inhalationsversuchen
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2216042A1 (de) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP1-analoge pharmazeutische Zusammensetzungen
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8614185B2 (en) 2009-05-04 2013-12-24 Centocor Ortho Biotech Inc. Fusion proteins of alpha-MSH derivatives and Fc
EP2427204B1 (de) 2009-05-06 2017-04-05 Janssen Biotech, Inc. Melanocortinrezeptor-bindende konjugate
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011013728A1 (ja) * 2009-07-29 2011-02-03 第一三共株式会社 経粘膜吸収性を付与したモチリン類似ペプチド化合物
CA2778890A1 (en) 2009-10-30 2011-05-05 Otsuka Chemical Co., Ltd. Glycosylated form of antigenic glp-1 analogue
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
CN103003300B (zh) 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
EP2588490B1 (de) 2010-07-02 2017-02-22 Angiochem Inc. Kurze und d-aminosäure-haltige polypeptide für therapeutische konjugate und ihre verwendungen
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
KR20140100947A (ko) 2011-11-03 2014-08-18 질랜드 파마 에이/에스 Glp-1 수용체 효능제 펩타이드 가스트린 접합체들
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Glp-1 펩티드의 조성물 및 그것의 제조
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
NZ704043A (en) 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AR098065A1 (es) 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3212218B1 (de) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip-agonisten-verbindungen und -verfahren
KR101825048B1 (ko) 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
EP3257524B1 (de) 2015-02-11 2020-08-26 Gmax Biopharm LLC Stabilisiertes lösungspräparat eines pharmazeutischen glp-1r-antikörperfusionsproteins
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁(杭州)生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
AU2023337288A1 (en) 2022-09-08 2025-03-13 Gmax Biopharm Llc Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides

Also Published As

Publication number Publication date
EP1405642A1 (de) 2004-04-07
PL343104A1 (en) 2001-07-30
JP2010270125A (ja) 2010-12-02
NO20006194D0 (no) 2000-12-06
RU2226402C2 (ru) 2004-04-10
US6348447B1 (en) 2002-02-19
NO327738B1 (no) 2009-09-14
DE69912434T2 (de) 2004-05-06
EP1094834A1 (de) 2001-05-02
CZ300873B6 (cs) 2009-09-02
EP1094834B1 (de) 2003-10-29
PL198802B1 (pl) 2008-07-31
ES2205845T3 (es) 2004-05-01
CA2321700A1 (en) 1999-12-16
DE69912434D1 (de) 2003-12-04
SE9802080D0 (sv) 1998-06-11
PT1094834E (pt) 2004-03-31
CZ20004491A3 (en) 2001-05-16
AU4669799A (en) 1999-12-30
HUP0103147A2 (hu) 2002-01-28
NZ506163A (en) 2004-10-29
WO1999064060A1 (en) 1999-12-16
CA2321700C (en) 2011-05-03
JP2002517468A (ja) 2002-06-18
NO20006194L (no) 2001-01-25
DK1094834T3 (da) 2004-01-05
ZA200004080B (en) 2001-12-24
AU738994B2 (en) 2001-10-04
HUP0103147A3 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
DE69912434D1 (de) Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung
RU2000133249A (ru) Фармацевтическая композиция для лечения функциональной диспепсии и/или синдрома раздраженной толстой кишки и новое применение веществ в ней
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
AR022368A1 (es) Procedimiento para administrar peptidos insulinotropicos
WO2002048192A3 (en) Amidated glucagon-like peptide-1
FI954941L (fi) Glukagonintapaisia insuliinitrooppisia peptidianalogeja, koostumuksia ja käyttömenetelmiä
PT758241E (pt) Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
DE122005000030I1 (de) Pregna-1, 4-dien-3, 20-dion-16-17-acetal-21-ester,Verfahren zur Herstellung, sowie diese enthaltendepharmazeutische Pr{parate.
DE69900816D1 (de) Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
GB9806632D0 (en) Peptide factor
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DE69932510D1 (de) Vaskularisierungsinhibitoren
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
FI943028A7 (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiint yvien, haavaumia aiheuttavien sairauksien hoitamiseksi
WO1992012715A3 (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
ATE242005T1 (de) P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes
KR950700726A (ko) 치료 또는 진단용 조성물, 그 제조방법 및 용도(composition for therapeutic or diagnostic use, process for its preparation and its use)
ATE109973T1 (de) Mundzubereitung zur verabreichung an bestimmter stelle des darmes.
AU3733295A (en) Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
EP1243595A4 (de) Mit bh4 fusionierte polypeptide

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee